Differential expression pattern of cardiovascular microRNAs in the human type-2 diabetic heart with normal ejection fraction

Rawal, Shruti; Ram, Thrishila Parshu; Coffey, Sean; Williams, Michael J.A.; Saxena, Pankaj; Bunton, Richard; Galvin, Ivor F.; Katare, Rajesh

doi:10.1016/j.ijcard.2015.08.161

Cited by 23 publications

(21 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Recent studies have demonstrated an association between miRs and DCM (23)(24)(25). The expression level of miR in the hearts of patients with DCM was found to be different when compared with that of healthy individuals (25,26).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Role of microRNAs in the pathogenesis of diabetic cardiomyopathy

Liu

2017

Biomedical Reports

View full text Add to dashboard Cite

Abstract. The morbidity of diabetes mellitus has been increasing annually. As a progressive metabolic disorder, chronic complications occur in the late stage of diabetes. In addition, cardiovascular diseases account for the major cause of morbidity and mortality among the diabetic population worldwide. Diabetic cardiomyopathy (DCM) is a type of diabetic heart disease. Patients with DCM show symptoms and signs of heart failure while no specific cause, such as coronary disease, hypertension, alcohol consumption, or other structural heart diseases has been identified. The pathogenesis of DCM is complex and has not been well understood until recently. MicroRNAs (miRs) belong to a novel family of highly conserved, short, non-coding, single-stranded RNA molecules that regulate transcriptional and post-transcriptional gene expression. Furthermore, recent studies have demonstrated an association between miRs and DCM. In the current review, the role of miRs in the pathogenesis of DCM is summarized. It was concluded that miRs contribute to the regulation of cardiomyocyte hypertrophy, myocardial fibrosis, cardiomyocyte apoptosis, mitochondrial dysfunction, myocardial electrical remodeling, epigenetic modification and various other pathophysiological processes of DCM. These studies may provide novel insights into targets for prevention and treatment of the disease.

show abstract

Section: Introductionmentioning

confidence: 99%

“…The expression level of miR in the hearts of patients with DCM was found to be different when compared with that of healthy individuals (25,26). Furthermore, analysis of miR expression levels in the hearts of various rat and mouse diabetic models also indicated the abnormal expression of miRNA.…”

Section: Introductionmentioning

confidence: 99%

Role of microRNAs in the pathogenesis of diabetic cardiomyopathy

Liu

2017

Biomedical Reports

View full text Add to dashboard Cite

show abstract

“…Rawal et al, demonstrated dysregulated expression of cardiac-specific miRs in diabetic individuals with normal EF, and further suggested that this early dysregulation together with some other clinically detectable changes may act as a catalyst for the clinical manifestations of DHD [206]. In line with this, several clinical and experimental studies have implicated the importance of miR dysregulation in cardiovascular diseases [194, 223–228].…”

Section: The Potential For Circulating Mirs To Determine Exercise Indmentioning

confidence: 96%

“…miRs can be released in a similar manner following exercise. Importantly our recent studies showed marked downregulation of muscle-specific miRs also known as myomiRs such as miR-1, -133 and -499 in the human diabetic heart [206]. Therefore, it is possible that exercise could activate the myomiRs in skeletal muscle which are released into the circulation (reviewed in [191]) which thereby restores the depleted level of myomiRs in the heart.…”

Section: Exercise-mediated Differential Expression Of Cardiovascular mentioning

confidence: 99%

Exercise mediated protection of diabetic heart through modulation of microRNA mediated molecular pathways

Lew

Pearson

Schwenke

et al. 2017

Cardiovasc Diabetol

Self Cite

View full text Add to dashboard Cite

Hyperglycaemia, hypertension, dyslipidemia and insulin resistance collectively impact on the myocardium of people with diabetes, triggering molecular, structural and myocardial abnormalities. These have been suggested to aggravate oxidative stress, systemic inflammation, myocardial lipotoxicity and impaired myocardial substrate utilization. As a consequence, this leads to the development of a spectrum of cardiovascular diseases, which may include but not limited to coronary endothelial dysfunction, and left ventricular remodelling and dysfunction. Diabetic heart disease (DHD) is the term used to describe the presence of heart disease specifically in diabetic patients. Despite significant advances in medical research and long clinical history of anti-diabetic medications, the risk of heart failure in people with diabetes never declines. Interestingly, sustainable and long-term exercise regimen has emerged as an effective synergistic therapy to combat the cardiovascular complications in people with diabetes, although the precise molecular mechanism(s) underlying this protection remain unclear. This review provides an overview of the underlying mechanisms of hyperglycaemia- and insulin resistance-mediated DHD with a detailed discussion on the role of different intensities of exercise in mitigating these molecular alterations in diabetic heart. In particular, we provide the possible role of exercise on microRNAs, the key molecular regulators of several pathophysiological processes.

show abstract

“…El genoma humano codifica más de 1.000 micro RNA (31) . En un modelo animal se comprobó un mecanismo de expresión genética y de hipertrofia de cardiomiocitos mediado a través de la reducción del micro RNA 133 (32) .…”

Section: Mecanismos Fisiopatológicos De La Cardiomiopatía Diabéticaunclassified

Cardiomiopatía diabética

2017

Rev. Urug. Cardiol.

View full text Add to dashboard Cite

La enfermedad coronaria, la hipertensión arterial y la diabetes son factores de riesgo independientes para el desarrollo de insuficiencia cardíaca y muerte. La cardiomiopatía diabética (CMD) es una de las etiologías frecuentes de cardiopatía en pacientes con diabetes tipo 1 y tipo 2. Si bien se suele plantear la CMD como la causa de la cardiopatía cuando se excluyen la hipertensión arterial, las valvulopatías y la enfermedad arterial coronaria aterotrombótica, estas coexisten con frecuencia e incluso también con la neuropatía autónoma cardiovascular. En los pacientes con CMD se puede demostrar mediante tests serológicos y por imagen alteraciones a nivel molecular, metabólico, mitocondrial, celular y tisular con infiltración grasa del músculo cardíaco, vinculadas a hiperglicemia, hiperinsulinemia y resistencia a la insulina, así como a lipotoxicidad por ácidos grasos libres, que son responsables del desarrollo de la CMD. Esta entidad primero determina disfunción diastólica del ventrículo izquierdo, más tarde disfunción sistólica e insuficiencia cardíaca. Se diagnostica mediante estudios serológicos de marcadores biológicos múltiples y por técnicas de imagen que evidencian la disfunción ventricular y mejoran la predicción pronóstica de enfermedad cardiovascular en diabéticos. En base a dichas pruebas se ha propuesto una clasificación por estadios o fenotipos clínicos de la CMD, que apunta a su diagnóstico precoz. Puede ser asintomática o ser responsable de síntomas y manifestaciones severas tales como insuficiencia cardíaca, arritmias y muerte súbita. Se puede asociar a hipertensión arterial, a enfermedad coronaria, a otras manifestaciones de microangiopatía y macroangiopatía aterotrombótica y a mortalidad cardiovascular. La prevención y el tratamiento intensivo multifactorial y personalizado de la diabetes, de todas sus alteraciones metabólicas y de la cardiopatía, mejoran la calidad y prolongan la vida. Se espera que investigaciones recientes, en proceso y futuras, determinen portentosos avances en la prevención y en el tratamiento de la CMD, que constituye una de las serias amenazas a la salud de la humanidad.

show abstract

Differential expression pattern of cardiovascular microRNAs in the human type-2 diabetic heart with normal ejection fraction

Cited by 23 publications

References 11 publications

Role of microRNAs in the pathogenesis of diabetic cardiomyopathy

Role of microRNAs in the pathogenesis of diabetic cardiomyopathy

Exercise mediated protection of diabetic heart through modulation of microRNA mediated molecular pathways

Cardiomiopatía diabética

Contact Info

Product

Resources

About